opnurasib,jdq443,tislelizumab
novartis,beigene
['jdq443', 'sclc', 'nsclc', 'kontrast01']
kontrast01 jdq443 phase 1 in kras g12c nsclc post soc rx. n=68 200mg bid. aes mostly g1-2 low freq alt/ast aes. orr 57.1%. dor 4.9mo. overall low aes (so far). nice orrs, dor to mature. await larger n and cns data and io combo data. #asco23 
Thoracic Oncologist @royalmarsdenNHS, Professor @ICR_London; Chair @BTOGorg; views are my own.